<div class="headers"><div>Figure 5. Proportion of patients with CD (GEMINI 2 and 3) who achieved the average daily composite score of APS <1 and LSFS <3 in the overall ITT (A), TNF antagonist-naive (S), and TNF antagonist-exposed (C) populations. ^Difference adjusted % change [VDZ - PBO] = % of VDZ patients who achieved the indicated subscore - % of PBO patients who achieved the indicated subscore. Lower 95% Cl limits >0 indicate statistical significance at a nominal significance level of 0.05. ‘Statistical significance and nonsignificance. APS, abdominal pain subscore; Cl, confidence interval; LSFS, loose stool frequency subscore; NS, nonsignificance; PBO, placebo; VDZ, vedolizumab.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Figure 5. Proportion of patients with CD (GEMINI 2 and 3) who achieved the average daily composite score of APS <1 and LSFS <3 in the overall ITT (A), TNF antagonist-naive (S), and TNF antagonist-exposed (C) populations. ^Difference adjusted % change [VDZ - PBO] = % of VDZ patients who achieved the indicated subscore - % of PBO patients who achieved the indicated subscore. Lower 95% Cl limits >0 indicate statistical significance at a nominal significance level of 0.05. ‘Statistical significance and nonsignificance. APS, abdominal pain subscore; Cl, confidence interval; LSFS, loose stool frequency subscore; NS, nonsignificance; PBO, placebo; VDZ, vedolizumab.</p></td>
</tr>
</tbody>
</table>
